0001127602-23-001340.txt : 20230112
0001127602-23-001340.hdr.sgml : 20230112
20230112161121
ACCESSION NUMBER: 0001127602-23-001340
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230110
FILED AS OF DATE: 20230112
DATE AS OF CHANGE: 20230112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Colangelo Dominick
CENTRAL INDEX KEY: 0001313403
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35280
FILM NUMBER: 23526041
MAIL ADDRESS:
STREET 1: 1000 WINTER ST.
STREET 2: SUITE 2200
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vericel Corp
CENTRAL INDEX KEY: 0000887359
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943096597
STATE OF INCORPORATION: MI
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 7349305555
MAIL ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC
DATE OF NAME CHANGE: 19960428
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2023-01-10
0000887359
Vericel Corp
VCEL
0001313403
Colangelo Dominick
C/O VERICEL CORPORATION
CAMBRIDGE
MA
02139
1
1
President and CEO
Common Stock
2023-01-10
4
M
0
39938
25.80
A
197004
D
Common Stock
2023-01-10
4
S
0
39938
27.132
D
157066
D
Stock Option (Right to Buy)
25.80
2023-01-10
4
M
0
39938
0
D
2023-03-06
Common Stock
39938
0
D
These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022.
These options, representing the right to purchase 55,001 shares, became exercisable on March 6, 2014, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal monthly installments over three years thereafter, contingent upon continued service to the Company.
/s/ Sean Flynn, as Attorney-in-Fact for Dominick C. Colangelo
2023-01-12